MNS Pharma Consultancy Limited Company accounts

COMPANY REGISTRATION NUMBER: 14665920

MNS Pharma Consultancy Limited

Unaudited Financial Statements

31 March 2025

MNS Pharma Consultancy Limited

Financial Statements

Year ended 31 March 2025

Contents	Page

Strategic report	1

Director's report	2

Statement of income and retained earnings	3

Statement of financial position	4

Statement of cash flows	5

Notes to the financial statements	6

MNS Pharma Consultancy Limited

Strategic Report

Year ended 31 March 2025

This report was approved by the board of directors on 29 December 2025 and signed on behalf of the board by:

Mr Sobhani
Director	Company Secretary

Registered office:

119 Jocelyns

Harlow

CM17 0BX

U.K.

MNS Pharma Consultancy Limited

Director's Report

Year ended 31 March 2025

The director presents his report and the unaudited financial statements of the company for the year ended 31 March 2025 .

Director

The director who served the company during the year was as follows:

Mr Sobhani

Dividends

Particulars of recommended dividends are detailed in note 9 to the financial statements.

This report was approved by the board of directors on 29 December 2025 and signed on behalf of the board by:

Mr Sobhani
Director	Company Secretary

Registered office:

119 Jocelyns

Harlow

CM17 0BX

U.K.

MNS Pharma Consultancy Limited

Statement of Income and Retained Earnings

Year ended 31 March 2025

			Period from
		Year to	15 Feb 23 to
		31 Mar 25	31 Mar 24
Note		£	£
Turnover	4	152,425	157,105

Cost of sales	69,509	53,182
	---------	---------
Gross profit	82,916	103,923

Administrative expenses		11,559	8,422
		--------	---------
Operating profit	5	71,357	95,501

	--------	---------
Profit before taxation	71,357	95,501

Tax on profit	8	15,982	20,859
		--------	--------
Profit for the financial year and total comprehensive income		55,375	74,642
		--------	--------

Dividends paid and payable	9	( 27,000)	( 31,000)

Retained earnings at the start of the year	43,642	–
	--------	--------
Retained earnings at the end of the year	72,017	43,642
	--------	--------

All the activities of the company are from continuing operations.

MNS Pharma Consultancy Limited

Statement of Financial Position

31 March 2025

	2025	2024
Note	£	£

Fixed assets

Tangible assets	10	11,250	–

Current assets

Cash at bank and in hand	122,356	114,495

Creditors: amounts falling due within one year	11	35,896	40,862
		---------	---------
Net current assets		86,460	73,633
		--------	--------
Total assets less current liabilities		97,710	73,633

Creditors: amounts falling due after more than one year	12	25,692	29,990
		--------	--------
Net assets		72,018	43,643
		--------	--------

Capital and reserves

Called up share capital	13	1	1
Profit and loss account		72,017	43,642
		--------	--------
Shareholders funds		72,018	43,643
		--------	--------

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These financial statements were approved by the board of directors and authorised for issue on 29 December 2025 , and are signed on behalf of the board by:

Mr Sobhani
Director

Company registration number: 14665920

MNS Pharma Consultancy Limited

Statement of Cash Flows

Year ended 31 March 2025

	2025	2024
	£	£

Cash flows from operating activities

Profit for the financial year	55,375	74,642

Adjustments for:
Depreciation of tangible assets	3,750	–
Tax on profit	15,982	20,859
Accrued expenses	77	1,074

Changes in:
Trade and other creditors	( 4,465)	48,919
	--------	---------
Cash generated from operations	70,719	145,494

Tax paid	( 20,858)	–
	--------	---------
Net cash from operating activities	49,861	145,494
	--------	---------

Cash flows from investing activities

Purchase of tangible assets	( 15,000)	–
	--------	---------
Net cash used in investing activities	( 15,000)	–
	--------	---------

Cash flows from financing activities

Dividends paid	( 27,000)	( 31,000)
	--------	---------
Net cash used in financing activities	( 27,000)	( 31,000)
	--------	---------

Net increase in cash and cash equivalents	7,861	114,494
Cash and cash equivalents at beginning of year	114,495	–
	---------	---------
Cash and cash equivalents at end of year	122,356	114,494
	---------	---------

MNS Pharma Consultancy Limited

Notes to the Financial Statements

Year ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 119 Jocelyns, Harlow, CM17 0BX, U.K..

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Turnover

The whole of the turnover is attributable to the principal activity of the company wholly undertaken in the United Kingdom.

5. Operating profit

Operating profit or loss is stated after charging:

		Period from
	Year to	15 Feb 23 to
	31 Mar 25	31 Mar 24
	£	£
Depreciation of tangible assets	3,750	–
	-------	----

6. Staff costs

The average number of persons employed by the company during the year, including the director, amounted to:

	2025	2024
	No.	No.
Administrative staff	1	–
Management staff	1	1
	----	----
	2	1
	----	----

The aggregate payroll costs incurred during the year, relating to the above, were:

		Period from
	Year to	15 Feb 23 to
	31 Mar 25	31 Mar 24
	£	£
Wages and salaries	67,200	52,200
Social security costs	1,763	948
	--------	--------
	68,963	53,148
	--------	--------

7. Director's remuneration

The director's aggregate remuneration in respect of qualifying services was:

		Period from
	Year to	15 Feb 23 to
	31 Mar 25	31 Mar 24
	£	£
Remuneration	52,200	52,200
	--------	--------

8. Tax on profit

Major components of tax expense

		Period from
	Year to	15 Feb 23 to
	31 Mar 25	31 Mar 24
	£	£

Current tax:

UK current tax expense	15,982	20,859
	--------	--------
Tax on profit	15,982	20,859
	--------	--------

9. Dividends

	2025	2024
	£	£
Dividends paid during the year (excluding those for which a liability existed at the end of the prior year )	27,000	31,000
	--------	--------

10. Tangible assets

	Motor vehicles
	£
Cost
At 1 April 2024	–
Additions	15,000
	--------
At 31 March 2025	15,000
	--------
Depreciation
At 1 April 2024	–
Charge for the year	3,750
	--------
At 31 March 2025	3,750
	--------
Carrying amount
At 31 March 2025	11,250
	--------
At 31 March 2024	–
	--------

11. Creditors: amounts falling due within one year

	2025	2024
	£	£
Accruals and deferred income	1,151	1,074
Other creditors	34,745	39,788
	--------	--------
	35,896	40,862
	--------	--------

12. Creditors: amounts falling due after more than one year

	2025	2024
	£	£
Corporation tax	15,983	20,859
Social security and other taxes	9,709	9,131
	--------	--------
	25,692	29,990
	--------	--------

13. Called up share capital

Issued, called up and fully paid

	2025		2024
	No.	£	No.	£
Ordinary shares of £ 1 each	1	1	1	1
	----	----	----	----

14. Analysis of changes in net debt

	At 1 Apr 2024	Cash flows	At 31 Mar 2025
	£	£	£
Cash at bank and in hand	114,495	7,861	122,356
	---------	-------	---------